23andMe Investor Day Presentation Deck slide image

23andMe Investor Day Presentation Deck

Human Genetics has the Potential to Double the Probability of Success in Drug Development Huw 000 Reasons for failure Wrong target • Hypothesized target not a critical node in disease pathogenesis • Safety issues associated with target Wrong drug Insufficient affinity/avidity; off-target effects • Poor PK/tissue penetration/inadequate dosing Wrong outcomes • Clinical outcome measure not related to biology of target • Clinical outcome measure not relevant in trial population Our rich database and translational focus has the potential to mitigate these and increase probability of success Wrong patients • Patients not properly stratified according to molecular, pathophysiological, or clinical heterogeneity • Trials underpowered to detect an effect in the right subset Copyright © 2022 23andMe, Inc. 23andMe 18
View entire presentation